1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario registrado en Universia


Opción 1: Descargar recurso

Detalles del recurso

Descripción

BACKGROUND Multiple myeloma (MM) is an hematological malignancy characterized by the accumulation of malignant plasma cells within the bone marrow. Osteolytic bone disease (OBD) is a major feature of myeloma, which leads to pathological fractures and hypercalcemia and affects dramatically the morbidity and mortality of patients. Bisphosphonates are the mainstay therapy of MM bone disease; though they are partially effective and related to adverse effects. Research for new therapeutic approaches are of great interest. OBJECTIVES Inhibition of the kinases SRC and MELK were evaluated as treatment of OBD. In addition, the role of galectin-1 (gal-1) in osteoclast (OCL) biology was investigated. RESULTS SRC inhibition by saracatinib inhibited in vitro OCL formation and function and affected osteoblast (OBL) activity. Saracatinib induced in vivo a high reduction of bone loss through the inhibition of bone resorption. Of note, MM cell proliferation and tumor burden remained unaltered following saracatinib treatment. // MELK inhibition by OTSSP167 inhibited OCL activity by decreasing progenitor viability as well as via a direct anti-resorptive effect on mature OCLs. In addition, OTSSP167 stimulated OBL function. This combined anti-resorptive and OBL-stimulating effect of OTSSP167 resulted in the complete prevention of lytic lesions and bone loss in vivo. // MM-bearing gal-1-/- mice showed higher tumor infiltration and reduced survival compared to wild-type mice. Microarray data analysis revealed a decrease of gal-1 expression during OCL formation, which was confirmed by in vitro OCL cultures. Gal-1-/- OCL cultured ex vivo caused higher bone resorption. Lastly, MM cells-OCLs co-cultures induced a stronger decrease of gal-1 expression in mature OCLs. CONCLUSIONS This thesis indicated SRC and MELK inhibition as promising therapeutic strategies for the treatment of myeloma OBD. Highlighting the implication of gal-1 in OCL biology and MM development warrants further investigation.

Pertenece a

ORBi Open Repository and Bibliography  

Autor(es)

Muller, Joséphine - 

Id.: 71282879

Idioma: francés  - 

Versión: 1.0

Estado: Final

Tipo de recurso: info:eu-repo/semantics/doctoralThesis  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

Requerimientos técnicos:  Browser: Any - 

Fecha de contribución: 09-may-2018

Contacto:

Localización:

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.